Rheumatology

A randomized controlled trial shows high-intensity interval and strength exercise improves multidimensional fatigue and quality of life in people with rheumatoid arthritis, with benefits lasting 12 months.

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.

UK Biobank data show people with rheumatoid arthritis have higher risks of heart disease, heart failure, and arrhythmias, with genetic analyses supporting causal links.

A first-in-human pilot trial suggests umbilical cord–derived mesenchymal stem cell eye drops may safely improve symptoms and inflammation in refractory dry eye, including Sjögren’s syndrome.

Randomised trial shows chiropractic care alters stress, immune, and neuroplasticity biomarkers in adults with spinal pain.

New data show hip osteoarthritis does not raise the risk of immune checkpoint inhibitor–induced inflammatory arthritis, while ICI-related arthritis is linked to improved survival.

Evidence from a clinical trial and long-term cohort studies suggests metformin, widely used in diabetes, may reduce knee osteoarthritis pain and lower future osteoarthritis risk.

A national cohort study shows rheumatoid arthritis remission rates in England and Wales have plateaued since 2018, with wide regional variation and delays before specialist referral limiting progress

A target trial emulation study finds no relapse reduction with cyclophosphamide added to glucocorticoids in eosinophilic granulomatosis with polyangiitis without poor-prognosis factors.

A qualitative study reveals how trust, communication, and clear responsibility between doctors influence vaccination uptake in patients with inflammatory rheumatic and musculoskeletal diseases.

New data identify age, anti-β2GP1 antibodies, and low C3 as key risk factors for cerebral small vessel disease in systemic lupus erythematosus, highlighting the need for targeted screening and risk stratification.

A university-based study finds a high prevalence of fibromyalgia symptoms, strongly linked to anxiety, stress, and lifestyle factors among students and staff.

New research identifies age, anti-β2GP1 antibodies, and low complement C3 as key risk factors for cerebral small vessel disease in systemic lupus erythematosus.

RA patients positive for anti-EBV EA-DR IgG antibodies show higher ACPA levels and increased disease activity, suggesting a link between Epstein–Barr virus immune responses and rheumatoid arthritis.

ASAS-PerSpA study finds Japanese patients with axial psoriatic arthritis have lower disease activity and better function than other regions, with notable differences in treatment patterns.

A scoping review shows machine learning models may help predict response to biologic and targeted synthetic DMARDs in rheumatoid arthritis, though validation gaps remain.

A new study shows that grip strength cannot be used as a proxy for core muscle endurance in axial spondyloarthritis, highlighting the need for targeted core assessments.

A six-year cohort study shows low muscle strength, not sarcopenia, is linked to increased falls risk in patients with rheumatoid arthritis, highlighting the importance of functional assessments.

Critically ill patients with systemic lupus erythematosus show reduced ICU survival, driven largely by renal dysfunction, with glucocorticoids potentially mitigating mortality risk.

Real-world data show switching to IL-17 inhibitors after TNF inhibitor failure improves treatment retention compared with TNF cycling in psoriatic arthritis.

A new review highlights kefir-derived peptides, probiotics and kefiran as promising natural strategies for bone health and osteoporosis prevention.

BSR has published an updated guideline on the safe use of csDMARDs, introducing new evidence, paediatric guidance, and risk-adaptive monitoring across the full life course.

Cardiac involvement was found in 35% of patients with EGPA, with pericarditis, myocarditis, and coronary vasospasms driving worse disease activity and prognosis.

New study finds early use of secukinumab in psoriatic arthritis offers no significant advantage over standard step-up treatment after one year.